- Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
- Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
- Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
- Neurocrine Biosciences to Participate at Investor Conferences in March
- Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
More ▼
Key statistics
As of last trade Neurocrine Biosciences Inc (NBIX:NSQ) traded at 131.77, -11.19% below its 52-week high of 148.37, set on Mar 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 132.65 |
---|---|
High | 133.65 |
Low | 131.54 |
Bid | 131.74 |
Offer | 131.80 |
Previous close | 132.54 |
Average volume | 688.71k |
---|---|
Shares outstanding | 100.58m |
Free float | 99.31m |
P/E (TTM) | 54.51 |
Market cap | 13.33bn USD |
EPS (TTM) | 2.43 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 17:36 BST.
More ▼